Democratic Oversight And Trump’s Rx Price Blueprint: Three Possible Routes
Executive Summary
House Democrats and the Trump Administration share an interest in taking on high drug prices. They probably won’t cooperate – but will the House actively block administrative changes?
You may also be interested in...
Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019
Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.
Lower Drug Costs Might End Perception US FDA Approval Standards Are Lower
CDER Director Woodcock says pricing and approval issues are becoming "conflated" but it is hard to change people's minds when they are "determinedly angry about something."
Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests
HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.